GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results

Up to 63.7% Reduction in Bone Marrow Blast Levels Restores Patient’s Endogenous…

GT Biopharma to Present at The Virtual 33rd Annual Roth Conference

BEVERLY HILLS, Calif., March 10, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…

New Wave: Annouces that Bloom Botanics Ltd. will Launch a New Line of CBD Products in Europe under the brand name ‘Newtriment’

TORONTO, Feb. 1, 2021 /CNW/ – NEW WAVE HOLDINGS CORP. (the “Company”…

New Wave Holdings subsidiary, Way of Will Inc. is pleased to announce its launch of high-quality mushroom products for Q1 2021

TORONTO, Jan. 14, 2021 /CNW/ – NEW WAVE HOLDINGS CORP. (the “Company” or “New…

Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group

Havn Life Has Joined the UK-Based Conservative Drug Policy Reform Group (CDPRG),…

Havn Life announces Voluntary Escrow of 6,300,000 Shares

The Voluntary Escrow serves further validates investors belief and support of Havn…

GT Biopharma Appoints Michael Handelman, CPA as Chief Financial Officer

BEVERLY HILLS, CA / ACCESSWIRE / November 18, 2020 / GT Biopharma,…

GT Biopharma Announces Publication of GTB-3550 TriKE Interim Results at the Prestigious 62nd American Society of Hematology (ASH) Annual Meeting

TAMPA, FL / ACCESSWIRE / November 12, 2020 / GT Biopharma, Inc. (OTCQB:GTBP)…

Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation

The research will be led by Prof. Dr. Gerhard Gründer, the only…